title: Composition of acellular pertussis and combination vaccines: a general review.
abstract: Since the development and introduction of the acellular pertussis vaccine in Japan in the early eighties, we have come a long way in using this component in combination with other vaccines. However, the basic problem in development of an effective and safe pertussis vaccine is that the antigens to induce complete protection against clinical pertussis and the precise mechanism by which pertussis vaccine confers immunity is yet unknown. Hence, the composition of future acellular pertussis vaccine remains an open issue. Recently, acellular pertussis vaccine has been licensed for the booster doses in the U.S.A. and for primary immunization of infants in Italy and Germany. A multicentric trial has been carried out to compare the serological response and adverse reactions of 13 acellular pertussis vaccines. These vaccines contained one or more of the four components, i.e. FHA, PT, 69 kDa OMP and fimbriae. All vaccines were associated with substantially fewer and less adverse reactions and were more immunogenic with respect to antibodies against the added antigens. DTP vaccines in the near future will have combinations of other components and the key antigen for combination will be acellular pertussis component which is going to replace whole cell pertussis component in DTP vaccines. In view of this, manufacturers like ourselves from the developing countries are still groping in the dark, uncertain whether we should have a single component acellular pertussis vaccine or multicomponent one. This will have a major impact on the cost of production, the final cost of the combination vaccines and the regulatory issues that we will have to tackle in view of the recent thinking on harmonization in the pharmaceutical industry.
authors.affiliation: Serum Institute of India Ltd., 212/2, Hadapsar, Pune, 411 028, India.
authors.forename: S S
authors.initials: SS
authors.lastname: Jadhav
authors.forename: S
authors.initials: S
authors.lastname: Gairola
mesh_terms: D002986:Clinical Trials as Topic; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D006801:Humans; D010567:Pertussis Vaccine / Q000737:chemistry*; D017778:Vaccines, Combined / Q000737:chemistry*
chemical_list: D015721:Diphtheria-Tetanus-Pertussis Vaccine; D010567:Pertussis Vaccine; D017778:Vaccines, Combined